➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:


Last Updated: September 25, 2021

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 077094

Email this page to a colleague

« Back to Dashboard

NDA 077094 describes RIBAVIRIN, which is a drug marketed by Aurobindo Pharma, Chartwell Rx, Teva, Zydus Pharms Usa, Navinta Llc, Beximco Pharms Usa, Heritage Pharma, and Sandoz, and is included in eleven NDAs. It is available from five suppliers. Additional details are available on the RIBAVIRIN profile page.

The generic ingredient in RIBAVIRIN is ribavirin. There are fifteen drug master file entries for this compound. Ten suppliers are listed for this compound. Additional details are available on the ribavirin profile page.
Summary for 077094
Applicant:Zydus Pharms Usa
Formulation / Manufacturing:see details
Pharmacology for NDA: 077094
Medical Subject Heading (MeSH) Categories for 077094
Suppliers and Packaging for NDA: 077094
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
RIBAVIRIN ribavirin TABLET;ORAL 077094 ANDA Cadila Healthcare Limited 65841-046 65841-046-03 168 TABLET, FILM COATED in 1 BOTTLE (65841-046-03)
RIBAVIRIN ribavirin TABLET;ORAL 077094 ANDA Cadila Healthcare Limited 65841-046 65841-046-10 1000 TABLET, FILM COATED in 1 BOTTLE (65841-046-10)

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrength200MG
Approval Date:Dec 5, 2005TE:ABRLD:No

Profile for product number 002

Active Rx/OTC/Discontinued:DISCNDosage:TABLET;ORALStrength400MG
Approval Date:Mar 16, 2007TE:RLD:No

Profile for product number 003

Active Rx/OTC/Discontinued:DISCNDosage:TABLET;ORALStrength600MG
Approval Date:Mar 16, 2007TE:RLD:No

Complete Access Available with Subscription

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.